Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
128.60
+0.06 (0.05%)
Feb 21, 2025, 4:00 PM EST - Market closed
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Intra-Cellular Therapies stock have an average target of 103.92, with a low estimate of 74 and a high estimate of 132. The average target predicts a decrease of -19.19% from the current stock price of 128.60.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intra-Cellular Therapies stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Buy | 4 | 5 | 5 | 5 | 4 | 4 |
| Hold | 2 | 2 | 2 | 2 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 21, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $119 → $132 | Strong Buy → Hold | Downgrades | $119 → $132 | +2.64% | Jan 31, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $108 → $132 | Buy → Hold | Downgrades | $108 → $132 | +2.64% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $107 → $132 | Buy → Hold | Downgrades | $107 → $132 | +2.64% | Jan 14, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $100 | Strong Buy → Hold | Downgrades | $100 | -22.24% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
688.57M
from 464.37M
Increased by 48.28%
Revenue Next Year
945.71M
from 688.57M
Increased by 37.34%
EPS This Year
-0.72
from -1.46
EPS Next Year
0.29
from -0.72
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 713.2M | 1.1B | 1.7B | |||
| Avg | 688.6M | 945.7M | 1.4B | |||
| Low | 656.2M | 848.9M | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 53.6% | 54.4% | 83.9% | |||
| Avg | 48.3% | 37.3% | 53.2% | |||
| Low | 41.3% | 23.3% | 23.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.37 | 1.32 | 5.87 | |||
| Avg | -0.72 | 0.29 | 3.51 | |||
| Low | -1.04 | -0.92 | 1.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 1,944.2% | |||
| Avg | - | - | 1,121.7% | |||
| Low | - | - | 408.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.